Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Core Insights - Pharvaris, a late-stage biopharmaceutical company, is focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][4] Presentation Details - Pharvaris announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting scheduled for November 6-10, 2025, in Orlando, Florida [1][2] - The oral presentations include: - Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema on November 8 at 4:43 p.m. ET [2] - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension on November 8 at 4:53 p.m. ET [2] - The poster presentations cover various aspects of Deucrictibant's efficacy and safety in treating hereditary angioedema, scheduled for November 7 [2] Company Overview - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability through oral therapies for the prevention and treatment of bradykinin-mediated angioedema attacks [4] - The company is currently evaluating the efficacy and safety of Deucrictibant in pivotal Phase 3 studies for both the prevention and on-demand treatment of HAE attacks [4]